Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

被引：0
作者：
Christopher R. Chapple
Victor W. Nitti
Vik Khullar
Jean Jacques Wyndaele
Sender Herschorn
Philip van Kerrebroeck
Mary Beth Blauwet
Emad Siddiqui
机构：
[1] Sheffield Teaching Hospitals,Department of Urology, Royal Hallamshire Hospital
[2] NYU Langone Medical Center,Department of Urology
[3] Imperial College,Urogynaecology Department, St. Mary’s Hospital
[4] University of Antwerp and University Hospital Antwerp,Department of Urology
[5] University of Toronto,Division of Urology
[6] Maastricht University Medical Center,Department of Urology
[7] Astellas Pharma Global Development,Department of Data Science, Biostatistics
[8] Astellas Pharma Europe Ltd,undefined
来源：
World Journal of Urology | 2014年 / 32卷
关键词：
Mirabegron; Overactive bladder; β; -Adrenoceptor agonist; Onset of action ;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1565 / 1572
页数：7
相关论文
共 146 条
[41]  
Pieper K(undefined)undefined undefined undefined undefined-undefined
[42]  
Gray M(undefined)undefined undefined undefined undefined-undefined
[43]  
Steers WD(undefined)undefined undefined undefined undefined-undefined
[44]  
Gentili A(undefined)undefined undefined undefined undefined-undefined
[45]  
Weiner DK(undefined)undefined undefined undefined undefined-undefined
[46]  
Kuchibhatil M(undefined)undefined undefined undefined undefined-undefined
[47]  
Edinger JD(undefined)undefined undefined undefined undefined-undefined
[48]  
Brown JS(undefined)undefined undefined undefined undefined-undefined
[49]  
Vittinghoff E(undefined)undefined undefined undefined undefined-undefined
[50]  
Wyman JF(undefined)undefined undefined undefined undefined-undefined
12345678910